- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03765632
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Haematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1α Short Form (EFS) Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency (SCID) Due to Adenosine Deaminase Deficiency
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, WC1N 3JH
- Great Ormond Street Hospital For Children NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of written informed consent prior to any study related procedures. In this study consent must be provided by the parents/legal guardians and, where applicable according to local laws, a signed assent from the child
- Subjects ≥30 days and <18 years of age,
With a diagnosis of ADA-SCID based on:
- . Evidence of ADA deficiency, defined as: i. Decreased ADA enzymatic activity in erythrocytes, leukocytes, skin fibroblasts, or in cultured foetal cells to levels consistent with ADA-SCID as determined by the reference laboratory, or ii. Identified mutations in ADA alleles consistent with a severe reduction in ADA activity,
- . Evidence of ADA-SCID based on either: i. Family history of a first order relative with ADA deficiency and clinical and laboratory evidence of severe immunologic deficiency, or ii. Evidence of severe immunologic deficiency in subjects prior to the institution of immune restorative therapy, based on
Lymphopenia (absolute lymphocyte count <400 cells/mL) OR absence or low number of T-cells (absolute CD3+ count < 300 cells/mL), or
Severely decreased T lymphocyte blastogenic responses to phytohemagglutinin (either <10% of lower limit of normal controls for the diagnostic laboratory, or <10% of the response of the normal control of the day, or stimulation index <10), or
Identification of SCID by neonatal screening revealing low T cell Receptor Excision Circle (TREC) levels.
- Ineligible for or with no available matched family donor for allogeneic Bone Marrow (BM) transplantation, defined as the absence of a medically eligible HLA-identical sibling or family donor, with normal immune function, who could serve as an allogeneic bone marrow donor.
- Females of child-bearing age will be required to provide a negative pregnancy test 30 days prior to Visit 2.
- Subjects and their parents/legal guardians must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period and willing to return to the clinic for the follow up evaluation as specified in the protocol.
Exclusion Criteria:
- Ineligible for autologous hematopoietic stem cell (HSC) procedure.
- Other conditions which in the opinion of the Principal Investigator and/or Co-Investigators, contraindicate the harvest of bone marrow, the administration of Busulfan and the infusion of transduced cells, or which indicate an inability of the subject or subject's parent/legal guardian to comply with the protocol.
Haematologic abnormality, defined as:
Anaemia (Hb <8.0 g/dl). Evidence of bi/trilineage cytopaenia (haemoglobin <8 g/dl, neutrophils <0.5 x 109/L, platelets 50 x 109/L). Thrombocytopaenia (platelet count <50,000/mm3). Prothrombin time or partial thromboplastin time (PTT) >2 x upper limit of normal (ULN) (subjects with a correctable deficiency controlled on medication will not be excluded).
- Cytogenetic abnormalities of Peripheral Blood (PB), BM or amniotic fluid (if available). If cytogenetic testing has not been performed on cells from amniocentesis, assessment should be by karyotype, Comparative genomic hybridization (CGH), and or whole exome sequencing (WES).
- Prior allogeneic HSC transplant (HSCT) with cytoreductive conditioning.
Pulmonary abnormality, defined as:
- Resting O2 saturation by pulse oximetry <90% on room air.
- Chest X-ray indicating active or progressive pulmonary disease. Note: Chest X-ray indicating residual signs of treated pneumonitis is acceptable for eligibility.
Cardiac abnormality, defined as:
- Abnormal ECG indicating cardiac pathology.
- Uncorrected congenital cardiac malformation with clinical symptoms.
- Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension.
- Poor cardiac function as evidenced by left ventricular ejection fraction <40% on echocardiogram.
Neurologic abnormality, defined as:
- Significant neurologic abnormality revealed by examination.
- Uncontrolled seizure disorder.
- Known history of significant renal abnormality.
- Known history of significant hepatic or gastrointestinal abnormality.
Oncologic disease, defined as:
- Evidence of active malignant disease other than Dermatofibrosarcoma Protuberans( DFSP) 2.
- Evidence of DFSP expected to require anti-neoplastic therapy within the 5 years following the infusion of genetically corrected cells (if anti-neoplastic therapy has been completed, a subject with a history of DFSP can be included).
- Evidence of DFSP expected to be life-limiting within the 5 years following the infusion of genetically corrected cells.
- Known sensitivity to Busulfan.
- Confirmation of an infectious disease by deoxyribonucleic acid (DNA) polymerase chain reactions (PCR) positive at time of screening assessment according to local protocols/procedures (including HIV-1 and hepatitis B).
- The subject is pregnant or has a major congenital anomaly.
- Is likely to require treatment during the study with drugs that are not permitted by the study protocol.
- The subject has previously received another form of gene therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gene Therapy
Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
|
Busulfan is used for non-myeloablative conditioning
Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
Other Names:
Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival at 12 months post OTL-101 infusion
Time Frame: 12 Months
|
Overall survival is defined as the proportion of subjects alive
|
12 Months
|
Event free survival at 12 months post OTL-101 infusion
Time Frame: 12 Months
|
Event-free survival is defined as the proportion of subjects alive with no "event", an "event" being the resumption of Peg-Ada ERT or the need for a rescue stem cell transplant (SCT), or death
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival at 24 months post OTL-101 infusion
Time Frame: 24 months
|
Overall survival is defined as the proportion of subjects alive
|
24 months
|
Event free survival at 24 months post OTL-101 infusion
Time Frame: 24 Months
|
Event-free survival is defined as the proportion of subjects alive with no "event", an "event" being the resumption of Peg-Ada ERT or the need for a rescue stem cell transplant (SCT), or death
|
24 Months
|
Safety evaluation including infection rates
Time Frame: 12 and 24 months
|
12 and 24 months
|
|
Safety evaluation including performance outcomes
Time Frame: 12 and 24 months
|
12 and 24 months
|
|
Safety evaluation including immune reconstitution
Time Frame: 12 and 24 months
|
12 and 24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Claire Booth, Dr, Great Ormond Street Hospital NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Immune System Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- DNA Repair-Deficiency Disorders
- Primary Immunodeficiency Diseases
- Immunologic Deficiency Syndromes
- Severe Combined Immunodeficiency
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Busulfan
Other Study ID Numbers
- OTL-101-5
- 17IC04 (Other Identifier: UCL Great Ormond Street Institute of Child Health)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Combined Immunodeficiency Due to ADA Deficiency
-
University of California, Los AngelesOrchard Therapeutics; California Institute for Regenerative Medicine (CIRM)CompletedSevere Combined Immunodeficiency Due to ADA DeficiencyUnited States
-
University of California, Los AngelesWithdrawnSevere Combined Immunodeficiency Due to ADA DeficiencyUnited States
-
Fondazione TelethonCompletedSevere Combined Immunodeficiency Due to ADA DeficiencyItaly
-
Fondazione TelethonActive, not recruitingSevere Combined Immunodeficiency Due to ADA DeficiencyItaly
-
Shenzhen Geno-Immune Medical InstituteUnknownAdenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)China
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and Development; Horizon...RecruitingSevere Combined Immunodeficiency Due to RAG1 DeficiencySpain, Netherlands, Italy, Poland, Australia, Turkey, United Kingdom
-
National Institute of Allergy and Infectious Diseases...National Center for Advancing Translational Sciences (NCATS); Office of Rare... and other collaboratorsEnrolling by invitationOmenn Syndrome | Reticular Dysgenesis | Severe Combined Immunodeficiency (SCID) | XSCID | Leaky SCID | ADA SCIDUnited States, Canada
-
National Institute of Allergy and Infectious Diseases...TerminatedGrowth Failure | X-linked Severe Combined Immunodeficiency (XSCID) | Growth Hormone ResistenceUnited States
-
Leadiant Biosciences, Inc.CompletedSevere Combined Immunodeficiency | ADA-SCID | Adenosine Deaminase DeficiencyUnited States
-
Great Ormond Street Hospital for Children NHS Foundation...UnknownX-linked Severe Combined ImmunodeficiencyUnited Kingdom
Clinical Trials on Busulfan
-
Hospital Israelita Albert EinsteinUnknownAcute Leukemia | Immunodeficiency | Chronic Leukemia | Lymphoproliferative Disease | Myeloproliferative DiseaseBrazil
-
Institut Paoli-CalmettesUnknownAcute Myeloid Leukemia | Myelodysplastic SyndromeFrance
-
Shanghai Public Health Clinical CenterR&D Kanglin BiotechUnknownHIV Infections | AIDSChina
-
City of Hope Medical CenterSangamo Therapeutics; California Institute for Regenerative Medicine (CIRM)Active, not recruiting
-
Baylor Research InstituteGenzyme, a Sanofi CompanyCompletedLeukemia | Myelodysplastic SyndromeUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedSarcoma | Lymphoma | Leukemia | Brain and Central Nervous System Tumors | Metastatic Cancer | Retinoblastoma | Childhood Germ Cell TumorUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Alberta Health servicesUnknownHematologic MalignancyCanada
-
Institut Paoli-CalmettesNot yet recruitingAcute Leukemia | Myeloproliferative Neoplasm | Mielodysplasic Syndrome
-
University of ArizonaCompletedHematologic Neoplasms | Multiple Myeloma | Myelofibrosis | Anemia, Aplastic | Hemoglobinuria, ParoxysmalUnited States